Review Papers Against Their Own Results

 Quick Explanation Copied

Verdict: srep15029 is a credible, moderately-powered demonstration that MTHFD2 also localizes to the nucleus and can drive proliferation independently of its dehydrogenase activity, but it establishes localization plus a correlative proliferation effect rather than a defined nuclear mechanism MTHFD2 nuclear localization and dehydrogenase-independent proliferation.

 Long Explanation

What the paper actually showed. Using subcellular fractionation with mitochondrial-contamination controls and leptomycin B, the authors detected MTHFD2 in nuclear fractions of HCT-116, U-251 and HeLa cells and showed co-localization with EdU-labeled replication sites; tumor tissue IHC (breast cancer, melanoma) confirmed nuclear signal only in a subset of cells Nuclear MTHFD2 localization and replication-site co-localization.

The proliferation claim is overexpression-based. Doxycycline-induced MTHFD2 or the catalytically dead MTHFD2ΔNAD increased HCT-116 proliferation versus GFP control, implying an enzymatic-independent role ΔNAD mutant retains pro-proliferation effect. This is an inferred (not measured) non-enzymatic function: no nuclear-restricted construct was tested, so mitochondrial vs nuclear contributions remain unresolved — a limitation the authors themselves acknowledge.

How the field has since evolved. The moonlighting idea is now broadly supported by independent mechanisms: MTHFD2 stabilizes EXO1 via CDK1 and binds PARP3 for DNA repair, and interacts with CDK2/hnRNPs and m6A-modified HIF-2α mRNA Review of MTHFD2 moonlighting mechanisms. Conversely, enzyme-based pharmacology (DS18561882) recapitulates genetic deletion phenotypes in AML, showing the catalytic function is itself essential MTHFD2 catalytic inhibition in AML.

What would change the conclusion. If a nuclear-restricted MTHFD2 mutant lost the proliferation advantage, or if catalytic inhibitors fully rescued the phenotype, the non-enzymatic nuclear model would need revision. Confidence: moderate — the localization data are solid; the mechanistic nuclear role was, at publication, hypothesis-generating rather than demonstrated.

 BGPT Paper Review

Study Novelty

In 2015, a nuclear, dehydrogenase-independent role for a mitochondrial folate enzyme was genuinely surprising; later reviews confirm it seeded the moonlighting subfield.

Scientific Quality

Multi-technique approach (fractionation, leptomycin B, EdU, IHC, activity assay, coexpression across 8,097 datasets) with proper controls; main weakness is that the non-enzymatic proliferation effect relies on overexpression and lacks a nuclear-restricted construct to separate compartments.

Study Generality

The moonlighting concept applies broadly to one-carbon enzymes and multiple cancer types, though only a subset of tumor cells showed nuclear signal.

Study Usefulness

Redirected the field toward non-catalytic MTHFD2 functions (DNA repair, RNA processing) and shaped inhibitor-drug design logic, but offered no direct therapeutic handle itself.

Study Reproducibility

Methods are well described with named reagents and tools (CellProfiler, ModFit); no public data deposition or code shared, and key results are image-based, which complicates exact replication.

Explanatory Depth